with the awards, in recognition of its diverse product portfolio, rapid business growth and innovation focus of the company. As part of the company’s growth strategy, Sutures India is looking for suitable strategic/OEM/business partners for market expansion in the south east Asian countries like Myanmar, Philippines, Vietnam and Indonesia. Sutures India has a significant footprint in the Asian market, having presence in China, Taiwan, Malaysia, and Thailand. Apart from the substantial institutional sales, Sutures India has started building the brand by promoting its products globally to surgeons.

Sutures India in association with PFM Medical, Germany has launched Timesh and Tilene Blue, a range of titanized mesh for ventral and inguinal hernia surgeries. This titanized polypropyl-ene mesh is patented and uses the unique Plasma Activated Chemical Vapour Deposition (PACVD) technology. The mesh has been approved by the International Endohernia Society and has been featured in the IEHS guidelines. Timesh and Tilene Blue are offered in three light weight variants and in four sizes as sterile, single-use packs.

“Launching Timesh and Tilene Blue is a part of our
organisational strategy of delivering high quality, innovative surgical solutions at a reduced cost per procedure. One of the biggest strengths of Sutures India is having a large distribution network of over 1,500 active channel partners and a field force of more than 300. Thus, we are in a unique position to deliver personalised service to our customer. The initial response to the unique titanized mesh has been very positive,” said Dinesh Lodha, CEO, Sutures India.

As a part of the company’s product growth strategy, Sutures India is pursuing growth opportunities in high-road wound closure categories. The company is now focused on bringing comprehensive high-end wound closure solutions to the surgeons. The company is making significant investments in research and development to expand the product basket. One of the challenges faced by the healthcare is medical Inflation, trends indicate that India is one of the highest in the region. We are continuously engaged with surgeons and clinicians to help deliver high quality, innovative surgical solutions at a reduced cost per procedure.

“According to Deloitte India research, the Indian healthcare Industry is expected to likely grow at a CAGR of 23% to $280 billion by 2020. We are on a growth trajectory and over the next few years we are well placed to address the opportunities in the healthcare industry,” added Lodha.

Leave Comment